709004-41-1Relevant articles and documents
Design, synthesis and preliminary biological evaluation of indole-3-carboxylic acid-based skeleton of Bcl-2/Mcl-1 dual inhibitors
Liu, Tingting,Wan, Yichao,Liu, Renshuai,Ma, Lin,Li, Minyong,Fang, Hao
, p. 1939 - 1948 (2017)
The B-cell lymphoma-2 (Bcl-2) family proteins are attractive targets for cancer therapy. In our previous work, the structure-activity relationship of WL-276 was studied. According to the results, rhodanine derivatives show potent binding affinity for Bcl-2 and Mcl-1 protein and show weaker activity against Bcl-XLprotein. Based on the previous results, a new class of indole-3-carboxylic acid-based derivatives were designed and synthesized as Bcl-2/Mcl-1 dual inhibitors. Among them, compound 17 has a Kivalue of 0.26?μM for Bcl-2 protein and is better than WL-276. Furthermore, it inhibits the myeloid cell leukemia sequence 1 (Mcl-1) protein with a Kivalue of 72?nM. Especially, compound 31 can selectively acting on Bcl-2 and Mcl-1 protein but not Bcl-XLprotein, which has great significance for developing dual inhibitors targeting Bcl-2 and Mcl-1 protein, as well as specific antitumor abilities in cells.
Substituted 3 - indole Bcl - 2 protein inhibitor and preparation method and application
-
Paragraph 0088; 0094; 0097; 0118; 0119, (2018/06/14)
The invention discloses a substituted3-indole Bcl-2 protein inhibitor and a preparation method and an application thereof. The compound has a structure as shown in the general formula I or II. The compound of the invention has a strong inhibitory activity to Bcl-2 protein and can prevent or treat related mammalian diseases caused by abnormal expression of Bcl-2 protein. The invention also relates to a pharmaceutical application of a compound of the compound having the structure as shown in the general formula I or II.